Wockhardt shares surged 18.1% to hit an all-time high of ₹2,092.6 per share on BSE following the company's announcement of regulatory approval for its antibiotic product. According to Business Standard, the stock was trading 17.54% higher at ₹2,082.4 per share around 12:34 PM on May 29, 2026, though it had pared some gains from earlier highs. The stock has demonstrated exceptional momentum with 31% gains in the past week and 48% over the month, while recording 45% year-to-date growth. The stock had touched a year's low of ₹1,086.70 apiece on March 23, 2026, highlighting the significant recovery from recent lows. However, technical analysis shows the stock is entering overbought territory with an RSI of 72.3, suggesting potential profit-booking after the sharp rally.
In a regulatory filing dated May 28, Wockhardt announced it received authorisation from the Central Drugs Standard Control Organisation (CDSCO) for the import and marketing of its 'indigenously discovered and developed, first-in-class breakthrough' antibiotic, Zaynich (Zidebactam/Cefepime). The approval is for the treatment of adult patients (18 years and above) with complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases with concurrent Gram-negative bacteremia. The approval is supported by exceptional results from the pivotal ENHANCE-1 study (NCT04979806), a multinational, randomised, double-blind Phase 3 clinical trial evaluating the efficacy and safety of Zaynich compared with meropenem in patients with cUTI, including pyelonephritis. The study showed that 89% of patients treated with Zaynich achieved clinical cure and microbiological eradication, compared with 68.4% in the Meropenem arm, delivering a treatment advantage of 20.6%. Even more striking were the outcomes in high-risk bacteremia patients, where Zaynich posted an 89% response rate versus just 44% for Meropenem, highlighting its potential as a game-changing therapy in severe drug-resistant infections.
According to the company's disclosure, Wockhardt has submitted a New Drug Application (NDA) in the United States and a Marketing Authorisation Application (MAA) in the European Union for Cefepime/Zidebactam, and they are currently under regulatory review. Zaynich, an injectable antibiotic, has also received priority review, fast track and qualified infectious disease product (QIDP) designations by the United States Food and Drug Administration (US FDA) for complicated urinary tract Infections (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). The Clinical and Laboratory Standards Institute has assigned Cefepime/Zidebactam an investigational susceptible breakpoint of 64 mg/L, supporting its potential to cover extensively drug-resistant Gram-negative pathogens in critically ill patients. Prior to the Phase 3 programme, Zaynich was evaluated across nine Phase 1 studies and a Phase 2 clinical study involving patients with documented meropenem-resistant Gram-negative infections. The Phase 2 study, conducted across 15 leading tertiary care hospitals in India, demonstrated over 97% clinical efficacy across serious infections, including hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, bloodstream infections, complicated intra-abdominal infections, and cUTI.
The pharmaceutical and biotechnology major reported robust financial results for Q4 FY26, with consolidated net profit of ₹166 crore compared to a loss of ₹25 crore in Q4 FY25. As reported by the company, revenue from operations soared 30% year-on-year to ₹965 crore during the quarter under review, against ₹743 crore in the year-ago period. At an operational level, EBITDA stood at ₹196 crore for the reporting quarter, marking a 147% YoY surge from ₹79 crore in Q4 FY25. The company maintains a total market capitalisation of ₹32,948.54 crore as of May 29, 2026, according to data on the NSE. Despite the strong performance, technical indicators suggest the stock is trading above all 8 out of 8 key simple moving averages, indicating sustained strength in momentum, though the 14-day RSI of 72.3 suggests potential for some profit-booking after the recent sharp rally.
